



(51) International Patent Classification:

A61K 47/68 (2017.01) A61P 37/02 (2006.01)
A61K 45/06 (2006.01) C07K 16/24 (2006.01)
A61K 47/60 (2017.01)

(21) International Application Number:

PCT/US2024/058543

(22) International Filing Date:

04 December 2024 (04.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/606,284 05 December 2023 (05.12.2023) US
63/656,917 06 June 2024 (06.06.2024) US

(71) Applicant: **KODIAK SCIENCES INC.** [US/US]; 1200
Page Mill Road, Palo Alto, California 94304 (US).

(72) Inventors: **ZURBRIGGEN, Andreas Sebastian**; c/o Ko-
diak Sciences Inc., 1200 Page Mill Road, Palo Alto, Cali-
fornia 94304 (US). **NUSSBAUMER, Martin**; c/o Kodiak

Sciences Inc., 1200 Page Mill Road, Palo Alto, California
94304 (US). **DUCRY, Laurent**; c/o Kodiak Sciences Inc.,
1200 Page Mill Road, Palo Alto, California 94304 (US).
PERLROTH, Daniel Victor; c/o Kodiak Sciences Inc.,
1200 Page Mill Road, Palo Alto, California 94304 (US).
TO, Wah Yuen; c/o Kodiak Sciences Inc., 1200 Page Mill
Road, Palo Alto, California 94304 (US). **SU, Carrie Jiali**;
c/o Kodiak Sciences Inc., 1200 Page Mill Road, Palo Alto,
California 94304 (US).

(74) Agent: **LOZAN, Vladimir, S.**; KNOBBE, MARTENS,
OLSON & BEAR, LLP , 2040 Main Street, 14th Floor,
Irvine, California 92614 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

(54) Title: FORMULATIONS FOR DUAL VEGF/IL-6 INHIBITORS, ANTI-VEGF ANTIBODIES, AND CONJUGATES THERE-
OF




FIG. 6

(57) Abstract: The present disclosure provides formulations comprising antagonizing antibodies that bind to IL-6, fusion proteins thereof with VEGF Trap, and conjugates of either thereof, and methods of making and using same. The anti-IL-6 antibodies, fusion proteins, and conjugates thereof, and formulations thereof can be used therapeutically alone or in combination with other therapeutics to treat diseases. Also provided are formulations comprising anti-VEGF antibodies and conjugates thereof.

[Continued on next page]

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*